USA Archives

News and Trends 13 Sep 2022

Aldatu gets grant to develop Crimean Congo hemorrhagic fever test

U.S. biotech company Aldatu Biosciences has been awarded a $3 million Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). The award will fund the advancement of the company’s proprietary PANDAA technology platform and its specific application to the […]

September 13, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

First patient enrolled in phase 3 study of drug for Charcot-Marie-Tooth disease

The first patient has been enrolled in a phase 3 study of a treatment for type 1A Charcot-Marie-Tooth Disease (CMT1A) in the U.S., it was announced today (September 12). Charcot-Marie-Tooth disease is a group of inherited conditions that damage the peripheral nerves and a treatment is being developed by French biopharmaceutical company, Pharnext. The PREMIER […]

September 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 12 Sep 2022

SiSaf reveals positive preclinical data in siRNA program to treat osteopetrosis

SiSaf Ltd, an RNA delivery and therapeutics company, has announced positive data confirming safety and efficacy of its Bio-Courier next generation silicon stabilized hybrid lipid nanoparticles (sshLNP) as an effective non-viral delivery system for autosomal dominant osteopetrosis type 2 (ADO2) siRNA therapy. The data was presented at the American Society of Bone and Mineral Research […]

September 12, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 12 Sep 2022

Cuffless device worn 24/7 can lower blood pressure, says Aktiia

A company making cuffless monitors for blood pressure says a significant and sustained reduction has been achieved for patients wearing the monitor 24/7. The device, made by Aktiia, measures blood pressure at optimal times throughout the day and night and was used in a study on hypertensive patients using a data set of more than […]

September 12, 2022 - 2 minutesmins - By Liza Laws

News and Trends 9 Sep 2022

Beyond Biotech podcast 13: BioInnovation Institute, IASP

This week’s guests on the podcast are Bobby Soni, chief business officer at the BioInnovation Institute; and Harriet Edwards, International Association of Science Parks (IASP) media and community manager. We also have our weekly chat with global commercial real estate services company JLL, and this week it is with Travis McCready. IASP to host World […]

September 9, 2022

News and Trends 8 Sep 2022

Investment of €130M made by Merck’s MilliporeSigma for life-saving therapies

An investment of €130 million ($130 million) has been invested in Molsheim, France to strengthen manufacturing capabilities for single-use assemblies – a key technology for the production of Covid-19 vaccines and other life-saving therapies. The investment was made by MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA. It is the largest ever […]

September 8, 2022 - 2 minutesmins - By Liza Laws

News and Trends 8 Sep 2022

Integral Molecular joins FDA’s ISTAND program

Integral Molecular has been accepted into the U.S. Food & Drug Administration (FDA)’s ISTAND (Innovative Science and Technology Approaches for New Drugs) pilot program. The program supports, and was created to expand, the drug development tool types listed in the 21st Century Cures legislation. A major goal of the pilot program is to qualify these […]

September 8, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 8 Sep 2022

Arcutis Biotherapeutics acquires Ducentis BioTherapeutics in deal worth up to $400M

Arcutis Biotherapeutics, Inc. has entered into an agreement to acquire Ducentis BioTherapeutics Ltd., a privately held, preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases. Arcutis BioTherapeutics will acquire the outstanding shares of Ducentis for an upfront cash payment of approximately $16 million and Arcutis stock valued at approximately $14 million, […]

September 8, 2022 - 4 minutesmins - By Jim Cornall

In Depth 7 Sep 2022

The biggest private biotech investments in August 2022

The healthcare-focused companies Orna Therapeutics, F2G and Sironax bagged the biggest biotech investments in August 2022, with mRNA vaccines, genomics and fermentation technology attracting big funding rounds. As many took a well-deserved vacation in the month of August 2022, the world of biotech remained busy with fundraising. Sit back and browse our lists of the […]

September 7, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 7 Sep 2022

Lesaffre acquires genome editing company Recombia Biosciences

Lesaffre has acquired Recombia Biosciences, a biotech company based in the San Francisco Bay Area founded in 2019 based on technology licensed from Stanford University. This acquisition is the culmination of a strategic partnership initiated in 2020 to leverage Recombia Biosciences’ genome-editing technologies and accelerate the development of yeasts for sustainable production of fermented ingredients. […]

September 7, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 5 Sep 2022

First patient with peripheral T cell lymphoma dosed with Yingli Pharma’s linperlisib

The first patient has been dosed in a phase 2 trial looking at a drug to treat peripheral T cell lymphomas – a heterogenous group of generally aggressive neoplasms. Yingli Pharma made the announcement on Saturday (September 3) that patients were being dosed with linperlisib – a potent inhibitor of the delta isoform of PI3 […]

September 5, 2022 - 2 minutesmins - By Liza Laws

News and Trends 5 Sep 2022

Avacta’s drug targeting soft tissue sarcoma granted Orphan Drug Designation by FDA

A drug to treat soft tissue sarcoma has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). Clinical stage oncology drug company Avacta Group plc has produced a form of the generic chemotherapy, doxorubicin AVA6000. About Avacta’s drug The drug has been modified using the company’s pre|CISION technology and Affirmer […]

September 5, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

USA

Aldatu gets grant to develop Crimean Congo hemorrhagic fever test

First patient enrolled in phase 3 study of drug for Charcot-Marie-Tooth disease

SiSaf reveals positive preclinical data in siRNA program to treat osteopetrosis

Cuffless device worn 24/7 can lower blood pressure, says Aktiia

Beyond Biotech podcast 13: BioInnovation Institute, IASP

Investment of €130M made by Merck’s MilliporeSigma for life-saving therapies

Integral Molecular joins FDA’s ISTAND program

Arcutis Biotherapeutics acquires Ducentis BioTherapeutics in deal worth up to $400M

The biggest private biotech investments in August 2022

Lesaffre acquires genome editing company Recombia Biosciences

First patient with peripheral T cell lymphoma dosed with Yingli Pharma’s linperlisib

Avacta’s drug targeting soft tissue sarcoma granted Orphan Drug Designation by FDA

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!